Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Alzinova AB is a biotechnology company specializing in the research and development of therapies for Alzheimer's disease. The primary focus of Alzinova is to develop safe and effective treatments aimed at addressing the underlying causes of this neurodegenerative disorder. A notable feature of the company's product pipeline is its proprietary AβCC peptide technology, which is designed to selectively target toxic amyloid-beta oligomers, a known contributor to Alzheimer's pathology. This targeted approach aims to reduce the cognitive decline associated with the disease by mitigating the harmful effects of these oligomers on brain cells. Alzinova AB operates in the highly specialized biopharmaceutical sector, where advancements in medical science hold the promise of transforming patient outcomes. By concentrating on a disease that affects millions worldwide, the company occupies a critical role in the ongoing quest to combat Alzheimer's, fostering hope for innovative solutions in disease management. Headquartered in Sweden, Alzinova collaborates with research institutions and clinical partners, leveraging their scientific expertise to advance its therapeutic candidates through various stages of clinical development.
kr 0.02
+kr 0.00 (+12.50%)
EOD Jun 23, 2026 · Twelve Data
ROIC dropped from -13.46% to -16.35%, capital efficiency is deteriorating. Negative free cash flow of -kr 40M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 0.00
Net Income (TTM)
-kr 27M
▼ -27.8% YoY
Op. Margin
—
ROIC
-16.35%
▼ -2.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 49M
▼ -6.8% YoY
Op. Cash Flow (TTM)
-kr 24M
▲ +31.4% YoY
Net Debt
kr 481K
Cash & Equiv.
kr 319K
Continue Research
Alzinova AB (ALZ.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Alzinova AB scores 0/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Alzinova AB scores 0 out of 100 on Intrinsiqq's quality score, passing 0 of 4 checks, which makes it a lower-quality business on these measures. Recent fundamentals include a -16.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh ALZ.XSTO's valuation and scores 0/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.